Skip to main content
Fig. 1 | Critical Care

Fig. 1

From: What every intensivist should know about Tocilizumab

Fig. 1

Longitudinal course over 20 days after Tocilizumab administration in 16 critically ill COVID-19 patients (local ethical approval: 2020-00646). Box and whiskers blots together with colored area demonstrate circulating levels of a Interleukin (IL)-6, b C-reactive protein (CRP), c procalcitonin (PCT) and d leucocytes. Days 0 = Tocilizumab administration (8 mg/kg bodyweight, max: 800 mg)

Back to article page

Critical Care

ISSN: 1364-8535